A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework

The concept of principal surrogate developed in the causal inference framework (Frangakis and Rubin (Biometrics 58:21–29, 2002); Gilbert and Hudgens (Biometrics 64:1146–1154, 2008)) has drawn much attention in the field of biomarker research. Principal surrogates are defined based on the causal treatment effects in principal strata, which are constructed based on the joint distribution of the potential surrogate markers when a patient receives either the placebo or the treatment. The challenge of evaluating principal surrogates lies in the fact that half of these potential surrogate markers cannot be observed in most clinical trials. Therefore assessing the principal surrogacy of biomarkers is essentially a missing data problem. In this article, we propose a multiple imputation approach to evaluate candidate principal surrogate markers. The proposed method employs baseline variables to impute the missing potential surrogate markers. The stratum-specific causal treatment effects on the clinical endpoint are then estimated for each imputed dataset and the inference for surrogacy of a biomarker is based on the combined results over multiple imputations. Simulation studies are performed to evaluate the performance of the proposed method and the implementation of the method is illustrated using a vaccine study.

[1]  Tyler J VanderWeele,et al.  Principal Stratification -- Uses and Limitations , 2011, The international journal of biostatistics.

[2]  D. Rubin Multiple imputation for nonresponse in surveys , 1989 .

[3]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[4]  J. Pearl The International Journal of Biostatistics Principal Stratification — a Goal or a Tool ? , 2011 .

[5]  D. Rubin Statistics and Causal Inference: Comment: Which Ifs Have Causal Answers , 1986 .

[6]  R. Little Missing-Data Adjustments in Large Surveys , 1988 .

[7]  Michael R Elliott,et al.  A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials , 2010, Biometrics.

[8]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[9]  Julian Wolfson,et al.  Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials , 2010, Biometrics.

[10]  Dean Follmann,et al.  Augmented Designs to Assess Immune Response in Vaccine Trials , 2006, Biometrics.

[11]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[12]  D. Rubin Randomization Analysis of Experimental Data: The Fisher Randomization Test Comment , 1980 .

[13]  Ralf Bender,et al.  Generating survival times to simulate Cox proportional hazards models , 2005, Statistics in medicine.

[14]  T. VanderWeele Simple relations between principal stratification and direct and indirect effects , 2008 .

[15]  Peter B Gilbert,et al.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. , 2008, The annals of applied statistics.

[16]  Judea Pearl,et al.  Direct and Indirect Effects , 2001, UAI.

[17]  J. Robins,et al.  Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.

[18]  Peter B Gilbert,et al.  Comparing Biomarkers as Principal Surrogate Endpoints , 2011, Biometrics.

[19]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[20]  D. Basu Randomization Analysis of Experimental Data: The Fisher Randomization Test , 1980 .

[21]  D. Rubin Direct and Indirect Causal Effects via Potential Outcomes * , 2004 .

[22]  Tao Wang,et al.  Multiple imputation methods for multivariate one-sided tests with missing data. , 2011, Biometrics.

[23]  Ivan S. F. Chan,et al.  Vaccine Clinical Trials , 2010 .

[24]  Liqiu Jiang,et al.  Multiple Imputation Approaches for the Analysis of Dichotomized Responses in Longitudinal Studies with Missing Data , 2010, Biometrics.

[25]  Shein-Chung Chow Encyclopedia of Biopharmaceutical Statistics , 2010 .

[26]  Michael G Hudgens,et al.  Evaluating Candidate Principal Surrogate Endpoints , 2008, Biometrics.

[27]  Tom Greene,et al.  Related Causal Frameworks for Surrogate Outcomes , 2009, Biometrics.

[28]  Ivan S F Chan,et al.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.